glp-1 tirzepatide online Troubling Findings in Study of Compounders DietsMD.com Launches Doctor-Guided Online GLP-1

MASH resolution without worsening of fibrosis: 2.4 mg dose: 47% of participants (vs 14% placebo) 4.8 mg dose: 62% of participants (vs 14% placebo) 6.0 mg dose: 43% of participants (vs 14% placebo) Liver fat reduction of at least 30%: 2.4 mg dose: 63% of participants 4.8 mg dose: 67% of participants 6.0 mg dose: 57% of participants Placebo: 14% of participants Fibrosis improvement by at least one stage: Survodutide groups: 34-36% Placebo: 22% The percentage change from baseline in liver fat content after 48 weeks was a staggering 62% reduction in the 6.0 mg group, compared to just 5.7% in the placebo group

Data and documents, including the trial protocol, statistical analysis plan, clinical study report and blank or annotated case report forms, will be provided in a secure data-sharing environment

Semaglutide, a GLP-1 receptor agonist originally developed for type 2 diabetes management, has emerged as a treatment option for chronic weight management in adults with obesity or overweight conditions

18,19 There is a poor correlation between oesophageal transit and gastric emptying